Search - tctmd.com

Displaying 21 - 30 of 30

Sort: Relevancy | Date

Presentation TCT 2019

Optimizing LDL-C Management in Patients Undergoing Revascularization: More Than Just the Metal

Presenter: Ziad Ali

September 28, 2019

Presentation TCT 2019

The State of The Art in LDL-C Lowering: Urgent Needs and Unmet Opportunities

Presenter: R. Wright

September 28, 2019

Presentation JIM 2019

Log-linear association per unit change in LDL-C and the risk of CV disease-a statin tale

Presenter: Bernardo Cortese

February 15, 2019

Presentation JIM 2019

Optimal LDL levels in patients with ACS undergoing PCI

Presenter: Ferdinando Varbella

February 15, 2019

Presentation Controversies and Advances 2017

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Presenter: Sanjay Kaul

November 16, 2017

Presentation TCT 2017

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Presenter: Bernard J. Gersh, Robert A. Harrington, Wolfgang Koenig

October 30, 2017

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

Presentation TCT 2015

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

Presenter: Bernard J. Gersh, Stephen D. Wiviott

October 13, 2015

Presentation TCT 2015

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Evan A. Stein

October 13, 2015

Presentation TCT 2012

Late Breaking Clinical Trials: STAMPEDE (Bariatric Surgery) and PCSK9 (LDL Reduction)

Presenter: Elizabeth Jackson

October 23, 2012

Advertisement

Optimizing LDL-C Management in Patients Undergoing Revascularization: More Than Just the Metal

The State of The Art in LDL-C Lowering: Urgent Needs and Unmet Opportunities

Log-linear association per unit change in LDL-C and the risk of CV disease-a statin tale

Optimal LDL levels in patients with ACS undergoing PCI

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Late Breaking Clinical Trials: STAMPEDE (Bariatric Surgery) and PCSK9 (LDL Reduction)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content